Ultragenyx Pharmaceutical (RARE)

• Market cap: $3.33B
• 1 day: -0.52%
• 5 days: 4.16%
• 1 month: 13.93%
• 3 months: 25.05%
• 6 months: -9.14%
• Year to date: -15.94%
• 1 year: -34.49%
• 5 years: -63.59%
• 10 years: -65.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294